Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Farmers Insurance
Queensland Health
US Department of Justice
Johnson and Johnson
Chubb
Medtronic
Colorcon
Baxter

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,198,858

« Back to Dashboard

Which drugs does patent 9,198,858 protect, and when does it expire?

Patent 9,198,858 protects NUVESSA and is included in one NDA.

This patent has twelve patent family members in eight countries.
Summary for Patent: 9,198,858
Title:Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations
Abstract: The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
Inventor(s): Nordsiek; Michael T. (Wayne, PA), Balaji; Kodumudi S. (Landsdale, PA)
Assignee: Watson Pharmaceuticals, Inc. (Salt Lake City, UT)
Application Number:13/593,386
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,198,858

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,198,858

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,946,276 High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
McKesson
Teva
UBS
Fish and Richardson
Boehringer Ingelheim
Covington
Argus Health
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.